Furthermore, Tmunity Therapeutics Inc. recently registered a phase I trial (NCT04025216) to test the safety, tolerability, feasibility, and preliminary efficacy of targeting the Tn glycoform of MUC1 (TnMUC1) using CAR-T cells in TnMUC1-positive advanced cancers, including NSCLC. Here, MUC1 is linked to non-small cell lung carcinoma.